Table 4.
Summary of plasma voriconazole pharmacokinetic parameters in adolescents by CYP2C19 genotype status
| Parameter and genotype group (n)a | Median (range) at dosageb |
||
|---|---|---|---|
| 6 mg/kg IV loading dose | 4 mg/kg IV q12h | 300 mg orally q12hc | |
| AUC12 (μg·h/ml) | |||
| UM/EM (7)d | 9.26 (2.52–19.8) | 16.3 (6.27–30.9) | 14.6 (1.17–37.9) |
| HEM (12)e | 9.26 (4.36–21.6) | 32.3 (6.24–95.3) | 26.3 (5.59–46.5) |
| PM (2) | 10.6, 11.7 | 31.1, 37.0 | 30.3, 49.7 |
| Cmax (μg/ml) | |||
| UM/EM (7)d | 2.55 (0.66–4.02) | 2.95 (2.26–4.99) | 1.96 (0.18–3.92) |
| HEM (12)e | 2.49 (1.12–3.82) | 3.72 (1.71–9.99) | 3.59 (0.81–4.39) |
| PM (2) | 1.89, 2.34 | 3.72, 8.74 | 4.20, 5.88 |
a
UM, ultrarapid extensive metabolizer; EM, homozygous extensive metabolizer; HEM, heterozygous extensive metabolizer; PM, poor metabolizer.
b
Individual values for the PM type are given.
c
Only one subject (a 39.8-kg white female) received 150 mg orally q12h.
d
One UM was excluded from summary statistics on IV exposures due to concomitant use of phenytoin.
e
n = 13 for 4 mg/kg IV q12h and 9 for 300 mg orally q12h.